Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma.

Chih-Hsiung HsiehWen-Hui KuanWei-Lun ChangI-Ying KuoHsun LiuDar-Bin ShiehHsuan LiuBertrand TanYing-Jan Wang

Published in: Journal of biomedical science (2022)

signature in ESCC patients with poor prognosis, recognizes SOX17 as a transcriptional repressor of NRF2, and provides a promising strategy targeting SOX17/NRF2 axis to overcome resistance.

Keyphrases

poor prognosis
transcription factor
oxidative stress
long non coding rna
stem cells
rectal cancer
gene expression
locally advanced
radiation therapy
drug delivery
heat shock